|Application ||WB, IHC-P, FC, E|
|Calculated MW||64990 Da|
|Antigen Region||437-465 aa|
|Other Names||Eukaryotic translation initiation factor 2A, eIF-2A, 65 kDa eukaryotic translation initiation factor 2A, Eukaryotic translation initiation factor 2A, N-terminally processed, EIF2A|
|Target/Specificity||This EIF2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 437-465 amino acids from the Central region of human EIF2A.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||EIF2A Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions in the early steps of protein synthesis of a small number of specific mRNAs. Acts by directing the binding of methionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF- 2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon- dependent manner, whereas the eIF-2 complex binds methionyl-tRNAi to 40 S subunits in a GTP-dependent manner. May act by impiging the expression of specific proteins.|
|Tissue Location||Widely expressed. Expressed at higher level in pancreas, heart, brain and placenta|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EIF2A is a 65-kD protein that catalyzes the formation of puromycin-sensitive 80S preinitiation complexes (Zoll et al., 2002 [PubMed 12133843]).
Willis, K.L., et al. Virology 394(1):73-81(2009)
Spurgeon, M.E., et al. J. Virol. 83(19):9970-9982(2009)
Lu, W., et al. J. Biol. Chem. 284(36):24281-24288(2009)
Yang, J., et al. Mol. Cell. Biol. 29(8):2243-2253(2009)
Schewe, D.M., et al. Cancer Res. 69(4):1545-1552(2009)
Olsen, J.V., et al. Cell 127(3):635-648(2006)
If you have any additional inquiries please email technical services at email@example.com.